Beneficios no anticonceptivos de 0, 02 mg de etinilestradiol/2 mg de acetato de clormadinona administrados en un régimen de 24+4 días / Non-contraceptive benefits of 0.02 mg ethinylestradiol /2 mg chlormadinone acetate in a 24 +4 days intake regimen

Objetivo: Demostrar la influencia sobre las molestias emocionales y físicas (beneficios no anticonceptivos) experimentadas durante el primer año de uso de un anticonceptivo oral combinado (AOC) que contiene 0,02 mg de etinilestradiol (EE) y 2 mg de acetato de clormadinona (ACM) administrado en un régimen de 24 + 4 días de placebo. Diseño del estudio: Análisis adicional de las sensaciones subjetivas registradas en los diarios de 1665 participantes de un estudio de Fase III multicéntrico, no controlado, de administración múltiple, después de 13 ciclos de EE/ACM en un régimen de administración de 24 + 4 días, publicado previamente. Resultados: Se informó de menor frecuencia de molestias emocionales y físicas en el ciclo de medicación 13 en comparación con los datos en la admisión y en el ciclo 1. La incidencia de ánimo depresivo se redujo en 84,5 por ciento y 72,2 por ciento respectivamente, y la irritabilidad en 87,3 por ciento y 66,0 por ciento. Las cefaleas se redujeron en 75,5 por ciento y 74,7 por ciento, las molestias mamarias en 77,1 por ciento y 66,1 por ciento, y la dismenorrea preexistente en 77,9 por ciento y 67,6 por ciento respectivamente. El abandono prematuro del estudio a causa de las molestias fue marginal, y el perfil del sangrado fue aceptable. Conclusiones: Un AOC de baja dosis que contiene 0,02 mg de EE + 2 mg de ACM, administrado en un régimen de 24 + 4 días, reduce significativamente la mayor parte de las molestias emocionales y físicas que se presentan durante los ciclos espontáneos de las mujeres, y se combina con un adecuado perfil de sangrado.

Objective: To demonstrate the influence on physical and psychological complaints during the first year of intake of the combined oral contraceptive (COC) 0.02 mg ethinylestradiol (EE)/2 mg chlormadinone acetate (CMA), administered in a regimen of 24 days of CMA/EE intake followed by 4 days of placebo intake. Study design: The subjective feelings of non-contraceptive benefits registered in women's diaries of 1,665 subjects participating in a multicentre, uncontrolled, multiadministration, Phase III trial, published elsewhere, were analyzed post-hoc after 13 cycles intake of EE/CMA in a 24 +4 days intake regimen. Results: Emotional complaints were reported less frequently at medication cycle 13 compared with admission and cycle 1. Depressive mood was reduced by 84.5 percent and 72.2 percent, irritability by 87.3 percent and 66.0 percent; physical complaints were also reduced: headaches by 75.5 percent and 74.7 percent, breast discomfort by 77.1 percent and 66.1 percent; pre-existing dysmenorrhea by 77.9 percent and 67.6 percent. Premature termination due to complaints was only marginal, the bleeding profile was accepted. Conclusions: The low-dose COC, 0.02 mg EE/2 mg CMA, administered in a 24 +4 day regimen, reduces significantly most of the emotional and physical complaints occurring during spontaneous cycles of women, combined with an adequate bleeding profile.

[Study of effect of acupressure methods on pain in primary dysmenorrhea]

Primary dysmenorrhea is highly prevalent and causes much work loss and discomfort. Regard to critical role of women in family and society it necessitate that to betaken proper investment for improving their mental and physical health. In this study 100 student suffer from primary dysmenorrhea were selected by targeted sampling and take their in two equal groups, case [acupressure group] and control [sham group] randomly. Initially in addition to personal identity, we recorded their history of menstruation, physical activity, vital signs, menstrual pain intensity. Treatment was given during two consecutive menstrual cycles coincident with pain and bleeding by acupressure in case group, and pressure in control group in two time of 15 minutes and 30 minutes interval during 6 hours after onset of dysmenorrhea in each cycle. In case group the treatment was given on lumbar, abdomen, foreleg and ear points, and in control group on placebo points by single blind method. Pain rating was done with use of V.A.S [Visual Analgesic Scale] in 30 min, 1 hr, 2hr and 3hr interval after treatment. The results showed that mean pain scores before [8.2 +/- 1.6] and after [2.6 +/- 1.3] in case group have significant difference. Also there is significant difference between mean pain score before and after treatment in case and control groups [p<0.001]. This study showed that acupressure at specific points in lumbar, abdominal, ear reduce the pan intensity and psychic and mental due to primary dymenorrhea. Therefore acupressure could be used as a non-medicament, inexpensive and safe method in decrease of pain of dysmenorrhea in girl and women

Consequências da deficiência estrogênica nos anos da perimenopausa / Consequences os estrogen deficiency in the perimenopausal years

A perimenopausa tem sido reconhecida cada vez mais como uma entidade separada no processo da menopausa precoce ou tardio. A menopausa näo deve ser vista necessariamente como um declínio, mas sim pode ser uma experiência pessoal positiva e o começo de uma vida de transiçäo satisfatória. Esperar pela parada das menstruaçöes antes de iniciar tratamento näo tem uma base fisiológica.